Download Databook
Download Sample
Table of Content
NA : +1 804 441 9344
sales@towardshealthcare.com
Schedule a Meeting
June 2025
The global biotechnology & pharmaceutical services market size is calculated at USD 76.51 in 2024, grew to USD 80.7 billion in 2025, and is projected to reach around USD 130.56 billion by 2034. The market is expanding at a CAGR of 5.48% between 2025 and 2034.
The global biotechnology & pharmaceutical services market is widely experiencing growth propelled by the increasing demand for outsourcing, rising investment in R&D for novel drug discovery, and escalating consultancy to resolve regulatory concerns and develop potential products and other approaches. In the coming era, this market will have widespread opportunities in novel drug development, innovative services, and technological advancements, with a focus on targeted therapies and personalized medicines in both the biotechnology and pharmaceutical sectors.
| Metric | Details |
| Market Size in 2025 | USD 80.7 Billion |
| Projected Market Size in 2034 | USD 130.56 Billion |
| CAGR (2025 - 2034) | 5.48% |
| Leading Region | North America |
| Market Segmentation | By Service, By End Use, By Region |
| Top Key Players | Parexel International Corporation, The Quantic Group, IQVIA, Lachman Consultant Services, Inc., GMP Pharmaceuticals Pty Ltd., Concept Heidelberg GmbH, LabCorp, Charles River Laboratories, ICON plc., Syneos Health, Lonza, Catalent Inc., Samsung Biologics, Eurofins Scientific, WuXi AppTec, Novotech, Thermo Fisher Scientific Inc. |
Basically, biotechnology and pharmaceuticals are two main domains in which products are either obtained from biological or synthetic sources. Nowadays, enormous technological advances in biological systems and the pharmaceutical field produce various products, including drug development, diagnostics, etc. By rising adoption of novel breakthroughs in R&D and regulatory considerations is boosting the expansion of the biotechnology & pharmaceutical services market. Both services are emphasizing on development of targeted drug therapies and personalized medicines, which have been showing raised demand in this growing market.
As AI has broad advantages in both the biotechnology and pharmaceutical fields, it offers enhanced effectiveness, rapid development, and inexpensive approaches to improve patient outcomes. AI algorithms enable analysis of huge amounts of data, assist in drug discovery, and simplify clinical trials. Moreover, AI supports in individual patients' data analysis (e.g., genetic, clinical) to develop the novel personalized medicine and targeted therapies in rising chronic diseases such as cancer, diabetes, and cardiovascular conditions, etc.
For instance,
Growing Technological Advancements and Focus on Personalized Medicine
Globally, the biotechnology & pharmaceutical services market is driven by boosting investments in R&D along with technological advancements like the acquisition of AI, digital tools, cloud -based technologies, data analysis, and clinical trial management, etc. Although by employing these techniques in both biotech and pharma services, a wide range of developments in personalized medicines and biologics are ongoing around the globe to fulfill the individual patient's needs, suffering from different genetic and chronic conditions.
Merging Data Security and Regulatory Compliance Issues
In the biotechnology and pharmaceutical services, a rising number of challenges in data security for outsourcing drug development, manufacturing, and clinical trials, to conserve sensitive data, proprietary formulas, and genetic research. Breaches may lead to legal liabilities, reputational concerns, and financial losses, as well as following various regulatory compliances such as the US FDA, EMA, GDPR, and HIPAA, is one of the difficult challenges growing in respective industries.
Escalating Global Collaborations and Novel Activities in R&D
The most widely established breakthroughs in both the biotechnology and pharmaceutical sectors are developing new collaborations with leading and debuting companies in drug development and other sectors. Also, the emerging activities in the research and development department for novel drug discovery approaches, services, and portfolios are enhancing the chances of the rising growth of the market. The supporting opportunity is increasing consultants provide expertise in different areas like regulatory affairs, product development, and quality management systems.
By service, the consultancy segment held the largest revenue share of the market, due to the rising need to cover difficult and ever-changing regulatory frameworks, particularly in the drug development and production field. These services support companies to understand and follow the regulations from authorities such as the U.S. FDA and EMA, which assures products won't experience any kind of withdrawals or recalls.
By service, the regulatory affairs segment is expected to be the fastest-growing over the projected timeframe. Due to the boosting globalization, i.e., the global expansion of biotechnology and pharmaceutical companies, which require proper guidance in diverse regulatory environments, and rising cost-effectiveness in outsourcing this segment will assist in reducing costs and maintaining the economic in respective organizations.
By end use, the pharmaceutical companies segment led the biotechnology & pharmaceutical services market in 2024. Contributing factors are increasing outsourcing of numerous services, such as regulatory compliance and product development, as well as the rise of global clinical trials. Also, it is fueled by the cost-effective R&D approaches, rising demand for specialized expertise, and the need for operational potential.
By end use, the biotechnology companies segment is expected to grow fastest in the upcoming years. Majorly factors involved in the expansion of this segment are boosting research and development (R&D) expenditure, the enhanced advances for therapies, and significant demand for biological products and biosimilars in different disorders.
North America held a significant revenue share of the market, due to rising expenses on the R&D department in both the biotech and pharma fields, along with accelerated outsourcing demands. Also, the emerging technological advancements in the production of innovative drug candidates and gene therapy, cell therapy, and bioinformatics are expanding the market over the world.
In North America, the US has been experiencing a major dominance of the market, with escalating investments in R&D by pharmaceutical and biotechnology companies, especially in sectors like personalized medicine, orphan drug development, and new drug discovery, leading to a high demand for specialized services.
For instance,
In Canada, the companies of the respective market are seeking novel ways to minimize costs and optimize efficacy in drug development and production are majorly driving the growth of the market. Along with this, the rising demand for outsourcing to CROs (Contract Research Organizations) and CMOs (Contract Manufacturing Organizations) enables industries to access expertise and resources at a reasonable cost and to boost timelines.
In ASAP, the services are expected to grow fastest during the forecast period, as there are growing developments in biologics and biosimilars, which require specialized expertise in production, quality control, and regulatory compliance, ultimately generating inexpensive and effective outsourcing as well. Primarily, countries like China, India, and South Korea are leading in genomics and oncology research with a focus on personalized approaches.
The Chinese government has taken steps in the implementation of national strategies to promote local biotech innovations, along with financial incentives, subsidies, and encouragement for science parks and start-up incubators. However, China has been investing its major contribution in R&D, especially in the development of novel drug candidates in both the biology and pharmaceutical fields.
For instance,
The market in India is driven by the combined factors such as a huge and varied population, a skilled workforce, inexpensive approaches, and favourable government policies. Over this, it is also experiencing novel creations, entrepreneurship, and investment, making it a promising area for the prospective growth.
For instance,
The European biotechnology & pharmaceutical services market is experiencing significant growth driven by the rising geriatric population, linked with chronic conditions are demanding advanced therapeutics with improved efficacy. Besides this, European regulatory frameworks are supporting drug discovery, R&D growth, and the arrival of novel medicines in both the domestic and global markets.
Germany is a global hub for clinical trials, which is helping to boost the development of drug discovery with success in research and development areas, to introduce more efficient and affordable drugs. Also, the rising trend for outsourcing specific pharmaceutical and biotechnology activities to specialized service providers, such as CROs and CDMOs, is driving market growth.
The UK has been widely investing in the R&D departments along with convenient, approachable services for the public. Majorly, it is also involved in new technologies, including AI, machine learning, and digital tools, to achieve highly developed and efficient approaches in pharmaceutical and biotechnology companies.
By Service
By End Use
By Region
June 2025
June 2025
June 2025
June 2025